Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial  by Ezekowitz, Michael D. et al.
Trial DesignApixaban compared with parenteral heparin
and/or vitamin K antagonist in patients with
nonvalvular atrial fibrillation undergoing
cardioversion: Rationale and design of the
EMANATE trial
Michael D. Ezekowitz, MBChB, DPhil, a,b Charles V. Pollack, MD, MA, c Paul Sanders, PhD, d Jonathan L. Halperin, MD, e
Judith Spahr, MPH, MEd, f Nilo Cater, MD, g William Petkun, MD, h Andrei Breazna, PhD, g Paulus Kirchhof, MD, i,j and
JonasOldgren,MD,PhDkPhiladelphia,Wynnewood, PA; London, Birmingham,UnitedKingdom;NewYork,NY;Münster,
Germany; and Uppsala, SwedenBackground Stroke prevention in anticoagulation-naïve patients with atrial fibrillation undergoing cardioversion has
not been systematically studied.
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,Nonvalvular atrial fibrillation (NVAF) is a modern
epidemic affecting 1 in 4 adults aged 60 years and older.1
Electrical or pharmacological cardioversion, or both togeth-
er are standard practice for restoring sinus rhythm in
selected patients with persistent atrial fibrillation (AF).2 The
risk of periprocedural thromboembolism may exceed 5%
when anticoagulation is inadequate.3,4 Therapeutic antic-
oagulation with a vitamin K antagonist (VKA) reduces the
risk to b1%.5-7 Current practice guidelines recommend
anticoagulation for at least 3 weeks before and at least 4
weeks after cardioversion for patients with AF lasting N48
hours or when the duration is uncertain.2,8,9 Secondary post
hoc analyses of the RE-LY trial,7 the ARISTOTLE trial,10 and
the ROCKET-AF trial11 suggest that the non-VKA oral
Table I. Clinical outcome event rates within 30 days postcardioversion in RE-LY,7 ARISTOTLE,10 and ROCKET-AF11 studies
RE-LY dabigatran
150 mg
RE-LY dabigatran
110 mg
RE-LY
warfarin
ARISTOTLE
apixaban
ARISTOTLE
warfarin
ROCKET-AF⁎
rivaroxaban
ROCKET-AF⁎
warfarin
Stroke† or systemic embolism 0.30 0.77 0.60 0 0 1.88 1.86
Major bleeding ‡ 0.60 1.70 0.60 0.30 0.20 18.75 13.04
Death§ n/a n/a n/a 0.6 0.5 1.88 3.73
n/a, Not applicable.
⁎ROCKET-AF combined event rates for cardioversion and ablation procedure.
†Both ischemic and hemorrhagic strokes.
‡ROCKET-AF combined major and nonmajor clinically relevant bleeding.
§ RE-LY did not report death rates within 30 days of cardioversion.
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heparin and warfarin for patients with NVAF undergoing
cardioversion and that event rates are very low (Table I). The
major limitation of these post hoc analyses, however, is the
prolonged period of anticoagulation preceding the cardio-
version. The need for more immediate cardioversion
frequently arises in patients presentingwith newly identified
AF. The X-VeRT trial12 was the first prospective trial of a
NOAC in the setting of cardioversion and found rivaroxaban,
an oral factor Xa inhibitor, comparable to VKA in patients
withNVAFundergoing cardioversionwithin 5 days or after 3
weeks and up to a maximum of 8 weeks of anticoagulation,
once again with very low event rates (0.5% and 0.6% for
efficacy and safety for rivaroxaban and 1.0% and 0.8% for
usual therapy, both not significantly different). No studies
have specifically evaluated a NOAC in a population of
patients who are anticoagulation naïve and who are
undergoing cardioversion. EMANATE will uniquely address
cardioversion in this population.
Apixaban
Apixaban is an orally active, reversible, direct inhibitor
of human coagulation factor Xa developed jointly by
Bristol-Myers Squibb (BMS) and Pfizer as an antithrom-
botic agent, now licensed globally for the prevention of
stroke and systemic embolization in patient with NVAF
and for treatment and prevention of venous and
thromboembolic disease.13
Objectives
The goal of this study is to assess clinical outcomes in
patients randomized to apixaban against conventional
anticoagulant care (parenteral heparin and/or a VKA) in
patients with recently detected AF considered for
card iovers ion. The protocol encourages an
image-guided approach (transesophageal echocardiogra-
phy [TEE] or computed tomography [CT]) or antic-
oagulation for a minimum of 3 weeks before
cardioversion.2,8 To avoid confounding by prior treat-
ment, the study focuses on patients who are antic-
oagulation naïve, excluding patients receiving any
anticoagulant for N48 hours during the index episode ofAF. Another aim of the study is to define predictors of a
successful outcome at 30 days after cardioversion.Design
This is a randomized, active-controlled, open-label
study of approximately 1,500 patients randomized 1:1
to apixaban or usual care (parenteral heparin and/or oral
anticoagulation with VKAs (goal international normalized
ratio [INR] 2.0-3.0, excluding other NOACs; Figure 1).
Anticoagulation is administered from randomization until
30 days after cardioversion. If cardioversion is not
performed, anticoagulation will be administered for a
maximum of 90 days. Clinical data including cardiover-
sion details, efficacy and safety outcomes, length of
in-hospital stay, and information regarding image guid-
ance are collected. The apixaban dose is 5 mg BID, with a
dose reduction to 2.5 mg BID if at least 2 of the following
exist: age N80 years, weight b60 kg, or serum creatinine
N1.5 mg/dL. Five doses of apixaban will be administered
before cardioversion to achieve steady-state blood levels.
If an immediate cardioversion is planned, a single 10 mg
dose (or 5 mg if the dose is down-titrated) is administered
at least 2 hours before cardioversion to more rapidly
bring exposure up to steady state. Investigators will use
their local label for dose adjustment guidance for
participants with renal impairment. (See Fig. 2).
Participants randomized to apixaban will transition
from their preexisting anticoagulant (oral and/or paren-
teral) of b48 hours as follows. For participants receiving a
VKA, apixaban is started when the INR is below 2.0. For
all NOACs, discontinue the drug and begin apixaban at
the next scheduled dose but no earlier than 12 hours after
the previous oral anticoagulant administration. For
low-molecular-weight heparin, apixaban should be
started at the time of the next scheduled dose and no
earlier than 12 hours after the previous parenteral
anticoagulation administration. For intravenous (IV)
infusion of unfractionated heparin (UFH), apixaban may
be started between 0 and 2 hours after IV UFH has been
stopped.
For participants randomized to usual therapy, stop
NOAC and start warfarin immediately, and start heparin at
Figure 1
EMANATE study design.
Figure 2
Participant flow.
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until the INR is above 2. In general, patients will bemanaged
according to the local clinician's usual practice and in a
manner consistent with the design of the study.
Statistical considerations
Therewas noprecedent for evaluating anticoagulation-naïve
patients in the setting of cardioversion. The warfarin-naive
cohort from the ARISTOTLE study14 was considered the
closest data set to the patients being recruited into this study.
The incidenceof stroke and systemic embolismwithin 30days
after randomization was 0.3% (1 stroke or systemic embolism
on apixaban and 3 events on usual care). The incidence of
major bleedingwas 0.45% (2 events on apixaban and 5 events
on usual care). To adequately power for noninferiority, 480
end points would be needed (similar to ARISTOTLE15). In this
study, follow-up is limited to 30 days after cardioversion or 90
days postrandomization. An estimated event rate of approxi-
mately 1% would require 48,000 participants, a number far
in excess of practicality. The figure of 1,500 patients
was considered clinically meaningful and achievable.
Kaplan-Meier curves of the time to first adjudicated stroke or
systemic embolism, first major bleeding event, and composite
of first major bleed and clinically relevant nonmajor bleed as
well as all-cause death will be generated.
Executive Committee
The Executive Committee (EC) comprises 5 academic
experts, 4 sponsor representatives (nonvoting), and a
biostatistician. The EC takes sole responsibility for the
study design, trial management, data analysis, and writing of
the manuscript. The EC reviews recommendations from the
Data Monitoring Committee (DMC) and oversees the
presentation and publication of the results. The EC is aided
by a clinical researchorganization andbydesignatednational
leaders in both cardiology and emergency medicine in the
participating countries. This trial is sponsored by BMS and
Pfizer. The authors acknowledge the editorial assistance of
Ms. Paulette Trent.
Data Monitoring Committee
An independent DMC is responsible for monitoring the
safety of participants in the study and recommending
alterations of the study to the EC and the sponsor. The
sponsor forwards decisions, which may include aggre-
gate analyses of end point events and safety data that are
not end points, to regulatory authorities as appropriate.
Study procedures
Screening
The investigator or designee at each participating
clinical site obtains written informed consent from each
participant, as well as contact and demographic informa-
tion, relevant medical history, and CHA2DS2VASc score,
and evaluates clinical laboratory results (Figure 2). Thepatient must meet inclusion and exclusion criteria,
including electrocardiographic confirmation of heart
rhythm (Tables II and III). These tables additionally
compare the inclusion and exclusion criteria from the
first completed trial of rivaroxaban (X-VeRT)16 and a
second ongoing trial of edoxaban (ENSURE-AF)17 that,
like EMANATE, prospectively evaluate novel anticoagu-
lants in the setting of cardioversion.
Randomization
Randomizationuses a centralized interactive voice-response
system. Study medication is dispensed in accordance with
local policies and procedures, with accounting recorded on
case report forms. Patients can be randomized and cardio-
verted on the same day, combining visits 1 and 2.
Cardioversion
The following details are recorded for each cardiover-
sion attempted: time and date attempted; whether
pharmacological, electrical, both pharmacological and
electrical, or spontaneous; local investigator interpreta-
tion of image guidance; type of image guidance; number,
date, and time of cardioversion attempts; rhythm status
after cardioversion; and adverse events (AEs).
Compliance
Compliance with apixaban is based on pill counts at the
time of cardioversion and at the end of the study. For
patients randomized to usual care, compliance is assessed
by INR monitoring.
Image guidance
In the event TEE or CT imaging identifies atrial thrombus,
cardioversion is deferred for at least 3 weeks. Assigned
anticoagulation continues, and imaging is repeated to
confirm resolution of thrombus before cardioversion. We
encourage investigators to continue assigned medication in
patients identifiedwith thrombus and repeat imaging studies
after 3 weeks.
Management of bleeding
Anticoagulation is interrupted in the event of clinically
significant bleeding and managed according to local
practice, which may include such measures as surgical
hemostasis, volume repletion, transfusion of blood
products, and for patients in the conventional therapy
arm, administration of protamine and supplemental
vitamin K fresh-frozen plasma, as deemed appropriate
by the treating physician. An antidote to apixaban is in
development but is not yet approved.18
Treatment transitions
At the end of the study or upon early withdrawal from
the study, the patient's subsequent management and
treatment are conducted by the treating physician
Table II. Inclusion criteria for EMANATE, X-VeRT, and ENSURE-AF
EMANATE X-VeRT ENSURE-AF
Participants with NVAF (as documented by ECG at visit 1)
indicated for cardioversion and initiation of anticoagulation
in accordance with the approved local label. Participants
presenting with atrial flutter with no evidence of AF are not
eligible for enrollment.
Hemodynamically stable NVAF
N48 h or of unknown duration
Ongoing NVAF lasting for at least 48 h but ≤12 m
Age ≥18 y (age ≥19 y for Korea only and age ≥20 y for
Japan only)
Men or women aged N18 y Male or female participants older than the
minimum legal adult age (country specific)
Written informed consent Written informed consent Signed informed consent form
The participant is willing to provide contact details for at
least 1 alternate person for study staff to contact regarding
their whereabouts, should the participant be lost to follow-up
over the course of the study. (subject to IRB/IEC approval)
Scheduled for cardioversion
(electrical or pharmacological)
of NVAF
Ongoing NVAF at the time of randomization
should be confirmed by any electrical tracing
(eg, routine 12-lead ECG, Holter monitor
rhythm strip, intracardiac electrogram,
or pacemaker) before randomization.
Female participants of childbearing potential must agree to use
a highly effective method of contraception throughout the
study and for at least 28 d after the last dose of
assigned treatment.
Women of childbearing potential
and men must agree to use
adequate contraception when
sexually active.
Duration and proof of AF during the previous
12 m can be confirmed by any electrical tracing
or a recording in the participant's medical records
(eg, medical chart, hospital discharge summary).
Participants who are willing and able to comply with
scheduled visits, treatment plan, and other
study procedures
Symptomatic participants with no known history of
AF and no prior electrical tracing or recording
of/about the cardiac rhythm available for the past
12 m may be randomized into the study if there
is reasonable belief that the current episode of AF
lasts for at least 48 h and no longer than 12 m.
Participant is planned for electrical cardioversion.
Participants with AF after a cardiac surgical
procedure (including catheter ablation) will be
allowed into the study, providing that they meet
all the other inclusion criteria and the time
from the surgery to randomization is no b30 d.
The investigator will be responsible for assessment of
risks relevant to the cardioversion procedure in such
participants.
ECG, Electrocardiogram; IRB, Institutional Review Board; IEC, Institutional Ethics Committee.
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oagulation strategy is necessary, the protocol recom-
mends the transition procedures contained in the
apixaban package insert.13
Participant withdrawal
Participants may withdraw from the study at any time
upon request, at the discretion of the investigator or
sponsor for safety or behavioral reasons, or because of
the inability of the participant to comply with the
required schedule of visits or procedures. Participants
withdrawn from the study are subsequently managed
according to conventional practice. Every effort will be
made to ensure follow-up for outcomes relevant to the
trial objectives.
Assessment
Clinical outcomes
Clinical outcomes are assessed by local investigators to
determine whether a protocol-specified outcome had
occurred. Events are recorded and reviewed by indepen-
dent adjudicators blinded to treatment allocation. Theclinical outcomes are the occurrence of acute stroke,
systemic embolism, all-cause death, major bleeding, and
clinically relevant nonmajor bleeding.
Acute stroke
Stroke is defined as a focal neurological deficit of
sudden onset, lasting at least 24 hours, not due to a readily
identifiable nonvascular cause. Strokes are classified as
primary ischemic, hemorrhagic, infarction with hemor-
rhagic conversion, or of unknown type if no imaging is
available in accordance with definitions established by
the American College of Cardiology.19 A diagnosis of
primary hemorrhagic stroke requires documentation by
imaging of hemorrhage in the cerebral parenchyma or in
the subdural or subarachnoid space or evidence of
hemorrhage obtained by lumbar puncture neurosurgery
or identified at autopsy. Nonhemorrhagic stroke is a focal
neurological deficit resulting from thrombosis or embo-
lism evident at 24 hours. Infarction with hemorrhagic
conversion requires absence of hemorrhage on initial
scan but evidence of hemorrhage on subsequent scan.
Stroke of unknown type is designated when brain
imaging is not available.
Table III. Exclusion criteria for EMANATE, X-VeRT, and ENSURE-AF
EMANATE X-VeRT ENSURE-AF
Having taken N48 h of an
anticoagulant (oral and/or
parenteral) immediately
before randomization
Severe, disabling stroke
(modified Rankin score of 4-5, inclusive)
within 3 m or any stroke within 14 d
before the randomization visit
AF considered to be of a transient or reversible nature
(such as in myocarditis, postsurgery
[unless the duration of AF postcardiac surgery is
>30 days, refer to inclusion criterion #4], ionic
disturbances, thyrotoxicosis, pneumonia,
severe anemia, etc.)
Contraindications to apixaban
or usual care (eg, VKA) in
accordance with the approved
local label
Transient ischemic attack within 3 d
before randomization
Participants with a history of LAA closure
(either by surgery or by a procedure)
Severe hemodynamically
compromised
participants requiring
emergent
cardioversion
Acute thromboembolic events or
thrombosis (venous/arterial)
within the last 14 d before
randomization
Participants with acute MI, stroke, acute coronary
syndrome, or percutaneous coronary intervention
within the previous 30 d or receiving DAPT
regardless of when the event has occurred
Hemodynamically significant mitral
stenosis, mechanical or biological
prosthetic valve, or valve repair
Acute MI within the last 14 d
before randomization
Participants with moderate or severe mitral stenosis,
mitral valve rheumatic disease, unresected atrial
myxoma, or a mechanical heart valve (participants
with bioprosthetic heart valves and/or valve repair
can be included) and/or other conditions,
such as pulmonary embolism, considered to be a
formal indication for conventional anticoagulation
-However, participants with AF and valvular heart
diseases such as mitral valve prolapse, mitral valve
regurgitation, and aortic valve disease are allowed
in the study.
Conditions other than AF that
require chronic anticoagulation
(eg, a prosthetic heart valve)
Cardiac-related criteria
(known presence of left atrial/LAA thrombus
before study inclusion, known presence of
atrial myxoma, known left ventricular or aortic
thrombus, valvular heart disease
[either hemodynamically significant mitral
valve stenosis or prosthetic heart valve])
Known presence of a thrombus in LAA, left atrium,
left ventricle, aorta, or intracardial mass
Simultaneous treatment with both
aspirin and a thienopyridine
(eg, clopidogrel, ticlopidine,
prasugrel) or simultaneous
treatment with both aspirin
and ticagrelor
Active bleeding or high risk of bleeding
contraindicating anticoagulant therapy
Signs of bleeding or conditions associated with high
risk of bleeding including major surgeries or
biopsies in the last 10 d
Pregnant females; breastfeeding
females; females of childbearing
potential who are unwilling or
unable to use a highly effective
method of contraception as
outlined in this protocol for the
duration of the study and for
at least 28 d after last dose
of investigational product
Concomitant drug therapies:
-Indications for anticoagulant therapy for a
condition other than AF (eg, VTE)
-Chronic ASA therapy N100 mg daily or DAPT
-Concomitant use of strong inhibitors of both
CYP3A4 and P-gp (ie, all HIV protease inhibitors
and the following azole antimycotic agents:
ketoconazole, itraconazole, voriconazole,
posaconazole, if used systemically)
Participants with any contraindication to
anticoagulant agents
Participation in other studies
involving investigational drug(s)
(phases 1-4) within 30 d before
the current study begins and/or
during study participation.
Note: participants cannot be
randomized into this study
more than once.
Concomitant conditions:
-Childbearing potential without proper
contraceptive measures, pregnancy, or breastfeeding
-Hypersensitivity to investigational treatment
or comparator treatment
-Calculated CrCl b30 mL/min
-Hepatic disease associated with coagulopathy
leading to a clinically relevant bleeding risk
-Severe conditions leading to life expectancy of b6 m
-Planned invasive procedure with potential for
uncontrolled bleeding (including major
surgery or cardiac catheterization)
-Inability to take oral medication
-Ongoing drug addiction or drug abuse
Participants with conditions associated with high
risk of bleeding such as a past history of
intracranial (spontaneous or traumatic),
spontaneous intraocular, spinal, retroperitoneal,
or intraarticular bleeding; overt gastrointestinal
bleeding or active ulcer within the previous year;
recent severe trauma, major surgery, or deep organ
biopsy within the previous 10 d; active infective
endocarditis; uncontrolled hypertension
(BP above 170/100 mm Hg); or hemorrhagic
disorder including known or suspected hereditary
or acquired bleeding or coagulation disorder
Severe acute or chronic medical or Any other contraindication listed in the local Participants receiving DAPT
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Table III (continued)
EMANATE X-VeRT ENSURE-AF
psychiatric condition or laboratory
abnormality that may increase the
risk associated with study
participation or investigational
product administration or may
interfere with the interpretation
of study results and, in the
judgment of the investigator,
would make the participant
inappropriate for entry into
this study
labeling for the comparator treatment or
experimental treatment
(eg, aspirin plus thienopyridine such as clopidogrel,
prasugrel, or ticagrelor) or anticipated to
receive such therapy
Investigational site staff members
directly involved in the conduct
of the trial and their family
members, site staff members
otherwise supervised by the
investigator, or participants who
are BMS/Pfizer employees
directly involved in the conduct
of the trial
Participation in a study with an investigational
drug or medical device within 30 d
before randomization
Participants receiving prohibited concomitant
medications (fibrinolytics, nonstudy
anticoagulants other than those used as a bridge
to/from study drug), chronic oral or parenteral
NSAID use for ≥4 d/wk
Previous randomization in this study Participants receiving chronic cyclosporine therapy
Inability to comply with the study procedures Participants with active liver disease or persistent
(confirmed by repeat assessments at least a week apart)
elevation of liver enzymes/bilirubin: alanine
transaminase or aspartate transaminase ≥3×
ULN; TBL ≥2× ULN (however, participants whose
elevated TBL is due to known Gilbert syndrome
may be included in the study)
Participants with renal failure (end stage renal disease,
calculated CrCl b15 mL/min)
Participants with hemoglobin b10 g/dL or platelet
count b100000 cells/mcL or white blood cell
count b3000 cells/mcL
Participants with preplanned invasive procedures
(other than routine endoscopy) or surgeries in
which bleeding is anticipated during the study period
Participants who received any investigational
drug or device within 30 d before randomization
or plan to receive such investigational therapy
during the study period
Women of childbearing potential without proper
contraceptive measures and women who are
pregnant or breastfeeding
Note: childbearing potential without proper
contraceptive measures (ie, a method of contraception
with a failure rate b1% during the course of the study
[including the observational period]. These methods
of contraception according to the note for guidance
on nonclinical safety studies for the conduct of human
trials for pharmaceuticals [CPMP/ICH/286/95,
modification] include consistent and correct use of
hormone containing implants and injectables,
combined oral contraceptives, hormone containing
intrauterine devices, surgical sterilization, sexual
abstinence, and vasectomy for the male partner)
Participants with the following diagnoses or situations:
-Active cancer undergoing chemotherapy, radiation,
or major surgery within the next 3 m;
-Significant active concurrent medical illness
or infection; life expectancy N6 m;
Participants who are unlikely to comply with the
protocol (eg, uncooperative attitude, inability to
(continued on next page)
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EMANATE X-VeRT ENSURE-AF
return for subsequent visits) and/or otherwise
considered by the investigator to be unlikely to
complete the study
Participants with a known drug or alcohol
dependence within the past 12 m as judged
by the investigator
Participants with any condition that,
in the opinion of the investigator,
would place the participant at increased
risk of harm if he/she participated in the study
LAA, Left atrial appendage; MI, myocardial infarction; DAPT, dual antiplatelet therapy; VTE, venous thromboembolism; ASA, aspirin; CYP3A4, cytochrome P450 3A4; P-gp,
permeability glycoprotein; HIV, human immunodeficiency virus; CrCl, Creatinine clearance; BP, blood pressure; NSAID, nonsteroidal anti-inflammatory drugs; ULN, upper limit of
normal; TBL, total bilirubin; CPMP, Committee for Proprietary Medicinal Products; ICH, International Conference on Harmonisation.
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Systemic embolism is defined by a clinical presentation
consistent with acute loss of blood supply to an
anatomical site supplied by a single artery, supported
by evidence from angiography, surgical specimens,
autopsy, or other objective testing.
Major bleeding
Clinically overt bleeding is defined as visible bleeding, or
signs or symptoms suggestive of bleeding with confirmatory
imaging that detects the presence of blood (eg, ultrasound,
CT, or magnetic resonance). The definition of major
bleeding adapted from the International Society on Throm-
bosis and Hemostasis20 requires clinically overt bleeding
accompanied by 1 or more of the following: a decrease in
hemoglobin of N2 g/dL; transfusion of N2 units of packed red
blood cells; bleeding that occurs in at least 1 of the following
critical sites: intracranial, intraspinal, intraocular (within the
corpus of the eye; thus, a conjunctival bleed is not an
intraocular bleed), pericardial, intraarticular, intramuscular
with compartment syndrome, retroperitoneal; or bleeding
that is fatal.
Clinically relevant nonmajor bleeding
The definition of clinically overt bleeding in the
EMANATE protocol is adapted from the International
Society on Thrombosis and Hemostasis guidelines.21
Clinically relevant nonmajor bleeding is an overt bleed
that compromises hemodynamics, leads to hospitalization,
produces subcutaneous hematoma N25 cm2, or 100 cm2 if
traumatic, intramuscular hematoma documented by ultra-
sonography, and epistaxis lasting N5 minutes or repetitive
(ie, 2 or more episodes of bleeding within 24 hours), or
leads to intervention (eg, packing or electrocoagulation);
gingival bleeding occurring spontaneously (ie, unrelated to
eating or tooth brushing) or lasting N5 minutes; spontane-
ous macroscopic hematuria lasting N24 hours after
instrumentation (eg, catheter placement or surgery);
macroscopic gastrointestinal hemorrhage, including at N1
episode of melena or hematemesis, if clinically apparent,and hemoptysis outside the context of pulmonary embo-
lism; or any other bleeding considered to have clinical
consequences such as medical intervention, unscheduled
contact (visit or telephone call) with a physician,
temporary interruption of study drug, or associated with
pain or impaired activities of daily life.
Length of hospital stay
The date and time of each hospital admission and
discharge will be recorded.
Adverse events
An AE is defined as any untoward medical occurrence
or worsening of a preexisting medical condition in a
participant administered an anticoagulant during the
course of the study.
Serious adverse events. Serious adverse events are
untoward medical occurrence that are life threatening or
fatal, require inpatient hospitalization or prolong an
existing hospitalization, result in persistent or significant
disability or incapacity, congenital anomaly or birth
defect, require intervention to prevent permanent
impairment or damage, or based on medical judgment,
are important medical events that place a participant in
jeopardy and require medical or surgical intervention to
prevent 1 of the aforementioned outcomes.Discussion
The novelty of this trial is the exclusive enrollment of
anticoagulant-naïve patients with recently detected AF
with a focus on enrolling those patients amenable to early
cardioversion. Also unique, if an immediate cardioversion
is planned, is the administration of a loading dose of 10 mg
(or 5 mg if the dose is down-titrated) of apixaban at least 2
hours before cardioversion. This is done to more rapidly
achieve a steady state of anticoagulation. For this reason,
potential participants are being actively identified in
hospital emergency departments. Image-guided cardiover-
sion with TEEs or CT scans is of special interest. Thus, the
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Echocardiography study,6 a multicenter, randomized trial
comparing a TEE-guided strategy of abbreviated therapeu-
tic anticoagulation with IV UFH started 24 hours before
cardioversion against conventional warfarin (INR 2.0-3.0)
for at least 3 weeks before cardioversion, provided
important background information. The investigators
enrolled 1,222 patients with AF of N2 days duration and
found no significant difference between the 2 strategies in
the rate of thromboembolic events for an 8-week period.
The rate of hemorrhagic eventswas lower in the TEE-guided
group (18 events [2.9%] vs 33 events [5.5%], P = .03). The
TEE group had a shorter time to cardioversion (mean ± SD,
3.0 ± 5.6 vs 30.6 ± 10.6 days). The authors concluded that
the strategy of TEE-guided treatment was a safe and effective
alternative to the conventional treatment strategy.6
Additional data relevant to cardioversion derive from a
post hoc subgroup analysis of the ARISTOTLE trial, in
which 540 participants underwent 743 cardioversions
and were followed up for 30 days after cardioversion. No
stroke or systemic embolic events occurred in patients
randomized to apixaban or warfarin. One major bleeding
event and 2 deaths were observed in each group.10 All
participants undergoing cardioversion in that trial had
been chronically anticoagulated before cardioversion, so
there was no information on the safety of apixaban in
participants newly presenting with AF or in those
patients naïve to anticoagulation in whom early cardio-
version is indicated. The EMANATE trial is designed to fill
this important information gap.
The first and largest post hoc analysis of cardioversion was
in the RE-LY trial, which found similarly low event rates in
groups treatedwithwarfarinor either of2dosesof dabigatran,
150 mg BID or 110 mg BID.7 The analysis provided grounds
for optimism regarding the potential use of a NOAC in this
setting (Table I). Subsequently, secondary analysis of the
ROCKET-AF trial described a similar experience with
rivaroxaban in a smaller number of patients insofar as
event rates were low (Table I).11 The ENGAGE-AF trial of
edoxaban also includedpatients undergoing cardioversion,
but the data are not currently available.
The only prospective trial to specifically address
cardioversion was the X-VeRT trial, which tested
rivaroxaban against usual therapy.12 Site investigators
decided whether to randomize participants to early (1-5
days after randomization) or delayed cardioversion
(between 21 and 56 days after randomization). Event
rates were low in both arms, with a nonsignificant trend
favoring rivaroxaban. Another ongoing prospective trial,
ENSURE-AF, is evaluating edoxaban against usual care in
patients with AF undergoing cardioversion.17
Limitations
EMANATE is an ongoing open-label trial. There is
precedent for conducting open-label anticoagulationtrials with blinded adjudication.12,17,22-24 The outcomes
of these completed trials are very similar to those of
completed double-blind trials,10,11,24,25 thus, confirming
the validity of this type of trial design.
We also describe the difficulty of conducting a
statistically valid noninferiority trial in the setting of
cardioversion due to the very large sample size required
because of low event rates reported in all the recent
cardioversion trials evaluating novel agents. This limita-
tion was recognized in the design of the comparable
X-VeRT and ENSURE-AF trials. We did consider a cohort
study using apixaban alone with comparison to historic
controls; however, the unique feature of EMANATE is the
anticoagulation-naïve population for which a historical
control group would not be available. There is evidence
that apixaban is being used in the setting of cardioversion
in certain sites without direct evidence to support this
approach. We do believe that this study fills an important
data gap and that the results of this study should bear
importantly upon future clinical practice.References
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